What the FDA labels say about taking them together
Octreotide and quinidine
Octreotide's FDA label of July 22, 2026 names quinidine in its drug interactions section; the quinidine label PlainMeds reads does not name octreotide. The octreotide label: “Limited published data indicate that somatostatin analogs including MYCAPSSA may decrease the metabolic clearance of compounds known to be metabolized by cytochrome P450 enzymes, which may be due to the suppression of …”
Check it at the source: the octreotide FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation); the quinidine FDA label on DailyMed (effective February 1, 2018, Sun Pharmaceutical Industries, Inc.).
What does the octreotide label say about quinidine?
Octreotide label, drug interactionsSince it cannot be excluded that octreotide may have this effect, other drugs mainly metabolized by CYP3A4 and which have a low therapeutic index (e.g., quinidine, terfenadine) should therefore be used with caution.
Mycapssa label (Chiesi USA, Inc., July 24, 2025), drug interactionsDrugs Metabolized by CYP 450 Enzymes Clinical Impact: Limited published data indicate that somatostatin analogs including MYCAPSSA may decrease the metabolic clearance of compounds known to be metabolized by cytochrome P450 enzymes, which may be due to the suppression of GH. Intervention: Concomitant use with other drugs mainly metabolized by CYP3A4 that have a narrow therapeutic index (e.g., quinidine) should be used with caution and increased monitoring may be required.
Source: FDA drug label (Mycapssa, NDA208232), Chiesi USA, Inc., effective July 24, 2025 (SPL set 58d80bc6-bdfb-4908-93e7-aace447c8d1a), via openFDA
Source: FDA drug label (Sandostatin), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set 4e2c9856-1836-49f0-9472-4dbeeb408f39), via openFDA; the full label on DailyMed
What does the quinidine label say about octreotide?
Quinidine's label (effective February 1, 2018) does not name octreotide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Quinidine Gluconate), Sun Pharmaceutical Industries, Inc., effective February 1, 2018 (SPL set 5023f053-fcc4-4c2c-aa59-9ec198ad185e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Octreotide | Quinidine | |
|---|---|---|
| Labeled for | Diarrhea | Atrial fibrillation |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $2.53 per mL 100 mcg/mL vial | $4.92 per tablet 324 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once